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Fixed airflow obstruction (FAO) can complicate asthma. Inflammation is a proposed under-
lying mechanism.
Objective
Our aim in this cross-sectional investigation was to evaluate the blood leucocyte pattern and
level of exhaled nitric oxide in asthmatics and non-asthmatics with or without FAO.
Methods
A total of 11,579 individuals aged�20 years from the US National Health and Nutrition
Examination Survey were included. They were grouped as: controls without asthma and
FAO (n = 9,935), asthmatics without FAO (n = 674), asthmatics with FAO (n = 180) and non-
asthmatics with FAO (n = 790). FAO was defined as post-bronchodilator FEV1/FVC < lower
limit of normal. Exhaled nitric oxide� 25ppb, blood eosinophil levels�300 cells/μL, and
blood neutrophil levels�5100 cells/μL were defined as elevated. Stratified analyses for
smoking and smoking history were performed.
Results
Elevated blood eosinophil levels were more common in all groups compared to the controls,
with the highest prevalence in the group with asthma and fixed airflow obstruction (p<0.01).
In a multiple logistic regression model adjusted for potential confounders including smoking,
the asthma groups had significantly higher odds ratios for elevated B-Eos levels compared
to the control group (odds ratio 1.4, (confidence interval: 1.1–1.7) for the asthma group with-
out fixed airflow obstruction and 2.5 (1.4–4.2) for the asthma group with fixed airflow
obstruction). The group with fixed airflow obstruction without asthma had higher odds ratio
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for elevated blood neutrophil levels compared to the controls: 1.4 (1.1–1.8). Smoking and a
history of smoking were associated to elevated B-Neu levels.
Conclusion
Fixed airflow obstruction in asthma was associated with elevated blood eosinophil levels,
whereas fixed airflow obstruction without asthma was associated with elevated blood neu-
trophil levels.
Introduction
Fixed airflow obstruction (FAO) is a non-reversible condition where the airflow during a
forced expiratory maneuver is impaired, manifesting spirometrically as a decreased post-
bronchodilatory ratio between forced expiratory volume during the first second (FEV1) and
forced vital capacity (FVC). This can be due to airway remodeling associated to asthma [1, 2],
or as seen in chronic obstructive pulmonary disease (COPD), damaged airways caused by
exposure to toxins such as cigarette smoke leading to structural changes [3]. A proposed path-
ologic mechanism in the development of FAO is a low-grade inflammation. Increased eosino-
phils in both blood (B-Eos) and sputum has been associated with FAO or lower lung function
in both asthmatics and non-asthmatics [4–8], though results have been contradictory [9–11].
Cigarette smoking has been reported to be related to an increase of leucocytes in blood and
sputum in both asthmatics and non-asthmatics [12, 13]. Elevated blood neutrophil (B-Neu)
count has also been associated with lower lung function both among asthmatics [14] and in
the general population [15]. The fraction of exhaled nitric oxide (FeNO) is mainly produced
by inducible NO synthase in the airway epithelium. FeNO seems to be more related to respira-
tory symptoms [16] than to FAO [17].
The aim of this cross-sectional analysis was to investigate how the inflammatory pattern
varied with FAO among asthmatics and non-asthmatics compared with in healthy controls;
and how this was influenced by smoking. Our hypothesis was that FAO would be related to
more inflammation, measured as higher levels of FeNO, B-Eos and/or B-Neu, but that the
inflammatory pattern would differ depending on whether or not asthma was present, indicat-
ing different pathophysiological mechanisms behind FAO.
Materials and methods
The participants were collected from the US National Health and Nutrition Examination Sur-
veys (NHANES) 2007–08, 2009–10 and 2011–12, a population based survey [18]. After exclu-
sion of subjects under 20 years of age and subjects who did not have spirometry data or where
the spirometries did not fulfill the American Thoracic Society (ATS) criteria regarding accept-
ability and reproducibility of measurements [19], the population consisted of 11,579 individu-
als (Fig 1). Subjects were divided into four groups: a reference group (controls) without
asthma and a FEV1/FVC ratio above the lower limit of normal (LLN) pre- or post-bronchodi-
lation (defined as without FAO), a group with asthma without FAO, a group with asthma with
FAO, and a group with FAO without asthma. These groups were compared regarding the lev-
els of the inflammatory markers.
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Spirometry, questionnaires and body measures
FEV1 and FVC were measured with an Ohio 822/827 dry-rolling seal volume spirometer. For
the subjects with a non-obstructive pattern (FEV1/FVC� 0.7 and above LLN), only pre-
bronchodilatory values were collected. However, for subjects with an obstructive pattern
(FEV1/FVC< 0.7 or below LLN [20, 21]), bronchodilation was performed with two puffs of
albuterol, followed by post-bronchodilation spirometry. The Hankinson reference values were
used and corrected for ethnicity [20, 21]. FAO was regarded as present if the FEV1/FVC ratio
was below LLN post-bronchodilation.
Questionnaire-reported variables (S1 Questionnaires) were obtained through interviews
performed by trained interviewers [22]. Hay fever was defined as present if the participant
reported an episode of hay fever in the preceding year. A smoking history of less than 100 ciga-
rettes defined never smoking. Participant with a smoking history in excess of that were divided
into current smokers and ex-smokers. Smoking history (pack-years) was based on the amount
of smoking reported. Ethnicity was defined as Mexican-American, other Hispanic, non-His-
panic white, non-Hispanic black, or other ethnicity, including multi-ethnic and Asian. Asthma
diagnosis was considered present if the participant reported current asthma diagnosed by a
health professional. Asthma morbidity was self-reported, defined as� 2 different asthma
symptoms reported in the preceding year [22]. This has been described in detail previously
[23]. Information about medication prescribed for wheezing in the preceding 12 months, and
for asthma in the preceding 3 months, and the use of inhaled corticosteroids, combinations of
inhaled corticosteroids and long-acting beta-2 agonists, oral corticosteroids, and leukotriene-
receptor antagonists in the preceding month was specified. Use of oral or inhaled corticoste-
roids during the two days preceding FeNO measurement was the subject of a specific question.
Body mass index (BMI) was calculated by dividing weight in kilograms by the square of
length in meters. The participants divided into groups: BMI< 25, 25–30 and> 30. A serum
cotinine� 3 ng/mL was regarded as a marker for cigarette smoke exposure [24].
Biomarkers
FeNO was measured using a handheld device with an electrochemical sensor (NIOX MINO;
Aerocrine, Stockholm, Sweden) at an exhalation rate of 50 mL/s. The mean was calculated
Fig 1. Flow-chart of included individuals.
https://doi.org/10.1371/journal.pone.0243109.g001
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after two reproducible measurements and used as the participant’s FeNO value. A
value� 25 ppb was defined as elevated in accordance with the ATS guidelines [25].
B-Eos and B-Neu were measured in venous blood using a Beckman Coulter HMX (Beck-
man Coulter, Fullerton, CA, USA). Both B-Eos and B-Neu were reported with a resolution of
100 cells/μL. B-Eos counts� 300 cells/μL [26, 27] and B-Neu counts� 5,100 cells/μL (upper
quartile) were defined as elevated, respectively.
Statistical analyses
The statistical analyses were performed in Stata/IC 15 (Stata Corp, College Station, TX, USA).
The three groups, asthma without FAO, asthma with FAO and FAO without asthma, were all
compared with the control group regarding baseline characteristics, and levels of FeNO,
B-Eos, and B-Neu. Normally distributed continuous variables were analyzed with Wald test
and categorical variables with Pearson’s chi-squared tests. Non-normally distributed variables
were analyzed non-parametrically with Wilcoxon rank sum test. Analyses were stratified for
smoking status (never, ex- and current) and smoking history (dichotomous variable, using 10
pack-years as cut-off) and the prevalence of elevated markers was analyzed in between the
case-groups. The asthma characteristics were compared between asthmatics with and without
FAO.
Adjusted multiple logistic regression models with the outcomes elevated levels of FeNO,
B-Eos, and B-Neu, adjusted for sex, ethnicity, age, steroid use in the preceding two days, study
year, cotinine levels, use of anti-inflammatory medications, and smoking status were used.
Interaction analyses in adjusted logistic models were done for sex and BMI respectively to eval-
uate effect modification by these variables.
The analyses took into account the complex multistage sampling and sampling weights pro-
vided by the NHANES [28]. A p value� 0.05 was considered statistically significant. Missing
data were handled using only complete cases.
Ethics statement
The National Centre for Health Statistics Research Ethics Review Board approved the proto-
cols (ERB protocol numbers #2006–2007 and #2011–2017). The participants provided written
informed consent.
Results
Characterization of the groups
The study group consisted of 11,579 individuals with a mean age of 45 years (range 20–79
years). In the whole population, 56% were never smokers, 22% ex-smokers and 22% current
smokers. In the control group and asthma without FAO group, the prevalence of never smok-
ers was almost 60%, while the asthma with FAO group had 26% never smokers and the FAO
without asthma group had 24%. The individuals in the two FAO groups were older than con-
trols and had been smoking more. In the FAO group without asthma, 5% had reported receiv-
ing a diagnosis of emphysema, 3% chronic bronchitis and 1% had been diagnosed with of
cancer in the lung. The subject characteristics are further described in Table 1.
Anti-inflammatory medication was mainly used in the two asthma groups. The group with
both asthma and FAO was prescribed more asthma medication (anti-inflammatory and or
including bronchodilator therapy) (78% vs. 58%, p = 0.005) and more anti-inflammatory med-
ication than asthmatics without FAO (43% vs. 26%, p = 0.002). They also more frequently
reported presence of at least 2 asthma symptoms (65% vs. 49%, p = 0.004) and a longer
PLOS ONE Asthma, fixed airflow obstruction and inflammation
PLOS ONE | https://doi.org/10.1371/journal.pone.0243109 December 3, 2020 4 / 13
duration of asthma: median (25–75th percentile) 21 years (11–38 years) vs. 17 years (8–28
years, p = 0.001). No difference in age at asthma onset was seen: 51% in the asthma without
FAO group had an onset of disease before 18 years of age vs. 57% in the asthma with FAO
group, p = 0.30.
Inflammatory patterns in the groups
The prevalence of elevated FeNO was 29% in the asthma without FAO group and 33% in the
asthma with FAO group, compared with 17% among controls (p< 0.001 for both) (Fig 2A).
Elevated FeNO was found in 16% of subjects with FAO without asthma, which was not signifi-
cantly different from among control subjects (p = 0.59). Elevated B-Eos was more common in
the asthma without FAO (30%), asthma with FAO (48%) and FAO without asthma (30%)
groups, compared with the control group: 23% (p< 0.001, p< 0.001, and p = 0.003, respec-
tively) (Fig 2B). Elevated B-Neu was also more prevalent in all case groups, asthma without
FAO 29% (p = 0.028), asthma with FAO 35% (p = 0.013) and FAO without asthma 34%
(p< 0.001), than among controls: 23% (Fig 2C). Elevated FeNO was more prevalent in both
asthma groups than in the FAO without asthma group (Fig 2A) (p� 0.001), and elevated


















Age� (mean ± SD) 44.2 ± 15 43.4 ± 16 0.34 48.4 ± 15 0.002 51.2 ± 15 <0.001
Age > 44 years 47% 45% 0.44 62% 0.002 68% < 0.001
Female 51% 67% < 0.001 59% 0.14 47% 0.018
Hay fever 16% 39% < 0.001 39% <0.001 15% 0.44
BMI group
< 25 31% 25% < 0.001 29% 0.90 40% < 0.001
25–30 34% 29% 35% 35%
� 30 35% 46% 36% 25%
BMI (mean ± SD)� 28.7 ± 6.6 30.8 ± 8.5 <0.001 29.7 ±7.6 0.29 27.0 ± 6.0 <0.001
Pack-years, median (25th–75th
percentile)†
0 (0–4.2) 0 (0–5) 0.043 8 (0–27) < 0.001 11.25 (0–30) < 0.001
Smoking history > 10 pack-years 17% 19% 0.27 47% < 0.001 50% < 0.001
Smoking
Never smoker 59% 57% 0.73 26% < 0.001 24% < 0.001
Ex-smoker 22% 22% 30% 30%
Current smoker 20% 21% 44% 46%
Elevated cotinine 25% 25% 0.94 49% < 0.001 50% < 0.001
Any of the below listed anti-
inflammatory medication in the
preceding month
1% 26% < 0.001 43% < 0.001 4% < 0.001
None 99% 74% < 0.001 57% < 0.001 96% < 0.001
ICS ± LABA 0% 13% 31% 2.5%
LTRA ± ICS ± LABA 0% 10% 8% 0%
OCS ± ICS ± LTRA ± LABA 1% 3% 4% 1.5%
�Wald test,
†Wilcoxon rank sum test.
Abbreviations: B-Eos: blood eosinophils; B-Neu: blood neutrophils; BMI: body mass index; FAO: fixed airflow obstruction; FeNO: fraction of exhaled Nitric Oxide; ICS:
inhaled corticosteroids; LABA: long acting beta agonist; LTRA: leukotriene receptor antagonist; OCS: oral corticosteroids
https://doi.org/10.1371/journal.pone.0243109.t001
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B-Eos was more common among the asthmatics with FAO than in the other groups (p = 0.004
versus asthma without FAO, and p = 0.003 versus FAO without asthma) (Fig 2B).
A higher prevalence of elevated FeNO was found in asthmatics compared with in controls
among never-smokers. Also, those in the FAO group without asthma who were never smokers
had an increased prevalence of elevated FeNO compared with controls (Table 2).
Among subjects with 10 or more pack-years’ smoking, elevated B-Eos was significantly
associated with asthma with FAO (Table 3).
Fig 2. Percent with elevated marker in the groups respectively: Panel a: FeNO; panel b: B-Eos; panel c: B-Neu. (a) Percent with elevated FeNO (�25ppb) in the groups:
Control: 17%, Asthma without FAO: 29%, Asthma with FAO: 33%, FAO without asthma: 16%, �� p< 0.001. (b) Percent with elevated B-Eos (�300 cells/μL) in the groups:
Control: 23%, Asthma without FAO: 30%, Asthma with FAO: 48%, FAO without asthma: 30%, � p< 0.05, �� p< 0.001. (c) Percent with elevated B-Neu (B-Neu�5100
cells/μL) in the groups: Control: 23%, Asthma without FAO: 29%, Asthma with FAO: 35%, FAO without asthma: 34%, � p< 0.05, �� p< 0.001. Abbreviations: FeNO:
fraction of exhaled Nitric Oxide, B-Eos: blood eosinophils, B-Neu: blood neutrophils, FAO: fixed airflow obstruction.
https://doi.org/10.1371/journal.pone.0243109.g002
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Table 2. Percent with elevated markers (FeNO�25ppb, B-Eos�300 cells/μL, B-Neu�5100 cells/μL) in the asthma and FAO groups compared with the control

















n = 5,495 n = 350 n = 53 n = 186
Elevated
FeNO
19% 33% < 0.001 49% 0.003 29% 0.017
Elevated
B-Eos
20% 24% 0.006 38% 0.12 27% 0.11
Elevated
B-Neu
19% 21% 0.56 19% 0.95 17% 0.61
Ex-smokers n = 2,077 n = 147 n = 47 n = 225
Elevated
FeNO
20% 34% 0.003 49% 0.008 23% 0.34
Elevated
B-Eos
25% 37% 0.014 61% < 0.001 29% 0.32
Elevated
B-Neu
21% 23% 0.64 24% 0.78 23% 0.59
Current
smokers
n = 2,019 n = 156 n = 76 n = 360
Elevated
FeNO
7% 15% 0.017 11% 0.16 5% 0.19
Elevated
B-Eos
32% 39% 0.039 43% 0.14 34% 0.63
Elevated
B-Neu
38% 57% 0.002 54% 0.068 49% 0.003
Abbreviations: B-Eos: blood eosinophils; B-Neu: blood neutrophils; FAO: fixed airflow obstruction; FeNO: fraction of exhaled Nitric Oxide
https://doi.org/10.1371/journal.pone.0243109.t002
Table 3. Percent with elevated markers (FeNO�25ppb, B-Eos�300 cells/μL, B-Neu�5100 cells/μL) in the asthma and FAO groups compared with controls, strati-
fied by total smoke exposure (< 10 or� 10 pack-years).














n = 8,228 n = 532 n = 107 n = 392
Elevated
FeNO
18% 33% < 0.001 44% < 0.001 21% 0.17
Elevated
B-Eos
21% 29% < 0.001 44% 0.004 26% 0.15
Elevated
B-Neu
21% 25% 0.21 28% 0.21 26% 0.086
Smoking� 10
pack-years
n = 1,707 n = 142 n = 73 n = 398
Elevated
FeNO
13% 16% 0.49 22% 0.092 11% 0.26
Elevated
B-Eos
32% 35% 0.43 53% 0.025 34% 0.60
Elevated
B-Neu
33% 46% 0.007 43% 0.23 42% 0.003
Abbreviations: B-Eos: blood eosinophils; B-Neu: blood neutrophils; FAO: fixed airflow obstruction; FeNO: fraction of exhaled Nitric Oxide
https://doi.org/10.1371/journal.pone.0243109.t003
PLOS ONE Asthma, fixed airflow obstruction and inflammation
PLOS ONE | https://doi.org/10.1371/journal.pone.0243109 December 3, 2020 7 / 13
Adjusted analysis
Elevated FeNO and elevated B-Eos were independently associated with asthma without FAO
and asthma with FAO, and elevated B-Neu was related to FAO without asthma after adjusting
for sex, ethnicity, BMI, age, steroid use in the preceding two days, study year, serum cotinine,
smoking habits, and use of anti-inflammatory medication (Table 4).
Interaction analyses for BMI and sex
The interaction analyses for BMI and sex showed significant interactions among asthmatics
without FAO for BMI and elevated FeNO for the group with BMI< 25 (adjusted odds ratio
(aOR): 4.0 (95% CI: 2.3–6.9)) compared with the group with BMI� 30 (aOR: 2.3 (1.6–3.4); pin-
teraction = 0.038). In the FAO without asthma group, there was an interaction with elevated
B-Eos, more common at BMI < 25, (aOR: 1.5 (1.0–2.4)) than at BMI� 30 (aOR: 0.74 (0.47–
1.2); pinteraction = 0.024). Female sex was significantly related to elevated FeNO in the FAO
without asthma group aOR: 1.8 (1.2–2.8) as compared with male sex (aOR: 0.82 (0.60–1.1); pin-
teraction = 0.003).
Discussion
Asthma with FAO was, like asthma without FAO, associated with elevated levels of FeNO and
B-Eos. However, asthmatics with FAO had the highest prevalence of elevated B-Eos of all
groups. Elevated B-Neu was associated with FAO and smoking, both with and without
asthma.
Both asthma with and without FAO were characterized by higher prevalence of elevated
FeNO and B-Eos compared with controls. As asthma is an inflammatory disease, elevated lev-
els of type-2 inflammatory markers are expected; we reported earlier that having increased lev-
els of both biomarkers was related to higher prevalence of asthma morbidity, without
accounting for presence of FAO [29]. These relations were consistent after adjusting for age
and smoking, which had previously been reported in the literature to associate with affected
B-Eos levels [30–33]. However, asthma with FAO was characterized by the highest prevalence
of elevated B-Eos, a finding in line with our recent study in which we reported that increased
levels of eosinophil activation markers were found in asthmatics with FAO [17]. This finding
is of interest, as elevated B-Eos could signal a treatable component of the disease, and with
more than half of the patients not using anti-inflammatory medication the preceding month,
there might be further room for optimization of treatment.
Elevated B-Neu levels were found in non-asthmatic subjects with FAO. This is probably
related to a large extent to smoking, known to be associated with increased B-Neu levels [12]
Table 4. Adjusted� odds ratios for elevated markers (FeNO�25ppb, B-Eos�300 cells/μL, B-Neu�5100 cells/μL) for the asthma and FAO groups in relation to the
control group in an adjusted logistic regression.
Biomarker Asthma without FAO P Asthma with FAO P FAO without asthma P
a�OR (CI) a�OR (CI) a�OR (CI)
Elevated FeNO 2.61 (2.09–6.97) < 0.001 3.82 (2.02–3.37) < 0.001 1.13 (0.86–1.48) 0.37
Elevated B-Eos 1.38 (1.13–1.67) 0.002 2.46 (1.43–4.22) 0.002 1.25 (0.95–1.65) 0.11
Elevated B-Neu 1.05 (0.82–1.35) 0.81 1.23 (0.74–2.04) 0.42 1.41 (1.09–1.86) 0.010
�Adjusted for sex, ethnicity, BMI, age, steroids in the preceding 2 days, study year, serum cotinine, smoking, anti-inflammatory medication in the preceding month.
Abbreviations: aOR: Adjusted odds ratio; B-Eos: blood eosinophils; B-Neu: blood neutrophils; BMI: body mass index; CI: 95% confidence interval; FAO: fixed airflow
obstruction; FeNO: fraction of exhaled Nitric Oxide
https://doi.org/10.1371/journal.pone.0243109.t004
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and also that many in this group probably have COPD. Sub analyses performed in different
smoking strata found this relation to be consistent only among current-smoking subjects. This
was also found in the group with asthma without FAO, and with a trend in the asthma with
FAO-group. Smoking in presence of respiratory or structural airway disease seems to relate to
further increase of B-Neu. Elevated B-Neu could reflect decreased ability to resist chronic
infections [34] in remodeled or fibrotic tissue, caused by smoking or injuries caused by other
respiratory diseases.
The prevalence of elevated FeNO was low in the FAO without asthma group. As smoking is
related to lower FeNO levels [35], we studied if this relation was consistent in different smok-
ing strata. This finding appears to be driven mainly by smoking subjects as in the analysis lim-
ited to never smokers, elevated FeNO was more prevalent in the FAO without asthma group
than among controls. Furthermore, we found a sex difference in subjects with FAO without
asthma, where elevated FeNO associated with FAO without asthma among women, but not
men. This could be explained by the same cut-off used in men and women despite differences
reported in the literature, with lower levels in women than in men due to smaller airways [36].
BMI was also associated to different inflammatory pattern in asthmatics without FAO, with
more active type-2 inflammation (FeNO and B-Eos) in subjects with normal BMI compared to
obese subjects. Possible explanations for this finding could be both altered inflammation
mechanisms in obese subjects with asthma, as higher proportion of neutrophilic asthma has
been described in asthma with obesity [37–39]. Another explanation is that in obese subjects
with asthma, respiratory symptoms might be more related to mechanical and ventilatory alter-
ations [40, 41] rather than type 2 inflammation.
FeNO is a marker reflecting local type-2 inflammation in the airways, whereas both B-Eos
and B-Neu are sampled in blood and do not necessarily mirror the inflammation in airway tis-
sue [42]. However, while increased B-Eos levels have been linked to worse lung function [6, 7],
the picture is more complicated when it comes to neutrophils. B-Neu is less correlated with
the levels in other compartments, such as bronchoalveolar lavage, bronchial biopsies or spu-
tum, than B-Eos [42, 43]. The increased amount of neutrophils in the airway lumen in COPD
is well-established [44, 45], and a part of the group with FAO with or without asthma is likely
to have COPD. Neutrophilia in airways and blood has, however, been associated with both bet-
ter [46] and worse pulmonary function over time [47, 48]. Our findings rather link elevated
B-Neu to airway disease (FAO, asthma) among smokers, as seen in the stratified analyses
(Tables 2 and 3).
There are some limitations in this study. Lung function was only measured at one time
point and there was no intervention with optimized treatment preceding the examinations.
This makes the reliability of the FAO diagnosis weaker; non-reversibility can also be a symp-
tom of under-treatment, though the asthma with FAO group reported using more medica-
tions. The cross-sectional study design does not allow for drawing conclusions on causality.
Furthermore, the FAO without asthma group was heterogeneous even if it could be assumed
that a significant proportion might be subjects with undiagnosed COPD and asthma. We
know that COPD is still underdiagnosed [49] and the same might apply to asthma as the cases
were defined based on self-reported physician-diagnosed asthma. In the light of this heteroge-
neity, this group rather represent the implications of fixed airflow obstruction than a common
etiology for the impairment. B-Eos and B-Neu measured in blood do not necessarily reflect the
levels in the airways [42, 43]. However, the advantage of their accessibility makes the clinical
impact of these valuable to scrutinize.
In conclusion, in asthma with FAO the inflammatory pattern was characterized by eosino-
philic inflammation and increased levels of FeNO, a pattern also seen in asthmatics without
FAO. However, the eosinophil pattern was even more pronounced in asthmatics with FAO.
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FAO in non-asthmatics was associated with elevated levels of B-Neu and our results suggested
a close association to current smoking. This indicates a need for further studies to evaluate the
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